Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Shu-Jia Chen"'
Autor:
Shu-Jia Chen, 陳婌佳
96
To support mobility, most hand-held wireless devices are powered by battery that has only a limited amount of energy. Therefore, energy efficiency becomes one of most important design issues in wireless networks. Our proposed mechanism is foc
To support mobility, most hand-held wireless devices are powered by battery that has only a limited amount of energy. Therefore, energy efficiency becomes one of most important design issues in wireless networks. Our proposed mechanism is foc
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/49736533142372630285
Autor:
Xiaoyu Jiang, Shuling Wang, Yijun Wang, Lin-Ping Shi, Shengbin Qi, Huiqing Jiang, Shiying Dou, Sheng-Xiong Chen, Ruo-Lin Cui, Ting Liu, Jiu-Na Zhang, Hongqun Liu, Shu-Jia Chen, Yongjuan Wang, Xiao-Li Xie, Xue Zhou
Publikováno v:
Journal of Cellular and Molecular Medicine
Triggering receptor expressed on myeloid cells‐1 (TREM‐1) exists in two forms: a transmembrane form and a soluble form (sTREM‐1). The levels of sTREM‐1 are elevated in supernatants of activated HSCs. However, the role of sTREM‐1 in HSC acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::007933606905265a7685b1c75807d545
https://doi.org/10.1111/jcmm.17033
https://doi.org/10.1111/jcmm.17033
Autor:
Jiu-Na Zhang, Yongjuan Wang, Ting Liu, Lin-Ping Shi, Xiaoyu Jiang, Xiao-Li Xie, Yijun Wang, Huiqing Jiang, Shu-Jia Chen, Shiying Dou, Ruo-Lin Cui, Xue Zhou, Sheng-Xiong Chen, Shuling Wang
Publikováno v:
World Journal of Gastroenterology. 27:4667-4686
Background Sorafenib is the first-line treatment for patients with advanced hepatocellular carcinoma (HCC). Y-box binding protein 1 (YB-1) is closely correlated with tumors and drug resistance. However, the relationship between YB-1 and sorafenib res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5453ead19ebcc0e69e6fb70ef8958eb0
https://doi.org/10.3748/wjg.v27.i28.4667
https://doi.org/10.3748/wjg.v27.i28.4667
Autor:
Ting, Liu, Xiao-Li, Xie, Xue, Zhou, Sheng-Xiong, Chen, Yi-Jun, Wang, Lin-Ping, Shi, Shu-Jia, Chen, Yong-Juan, Wang, Shu-Ling, Wang, Jiu-Na, Zhang, Shi-Ying, Dou, Xiao-Yu, Jiang, Ruo-Lin, Cui, Hui-Qing, Jiang
Publikováno v:
World Journal of Gastroenterology
BACKGROUND Sorafenib is the first-line treatment for patients with advanced hepatocellular carcinoma (HCC). Y-box binding protein 1 (YB-1) is closely correlated with tumors and drug resistance. However, the relationship between YB-1 and sorafenib res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5d853251617a2357145d8b3580012b37
https://pubmed.ncbi.nlm.nih.gov/34366628
https://pubmed.ncbi.nlm.nih.gov/34366628